These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 338900)
41. Comparison of the actions of 5-fluorouracil and ftorafur in Escherichia coli. Saunders PP; Chao LY Antimicrob Agents Chemother; 1977 Mar; 11(3):451-4. PubMed ID: 324392 [TBL] [Abstract][Full Text] [Related]
42. Effects of a fluorinated pyrimidinedione anti-cancer drug, 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FT), and related compounds on nigro-striatal dopaminergic neurons in the central nervous system. Toide K; Unemi N; Segawa T Arch Int Pharmacodyn Ther; 1985 Mar; 274(1):111-24. PubMed ID: 3925907 [TBL] [Abstract][Full Text] [Related]
43. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats. Kawaguchi Y; Nagayama S; Masuda H; Yasuda A Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982 [TBL] [Abstract][Full Text] [Related]
44. Comparing cell kinetic studies of the effect of ftorafur and 5-fluorouracil on the L 1210 ascites tumor. Schultze B; Jellinghaus W; Weis G; Müller V; Maurer W J Cancer Res Clin Oncol; 1981; 100(1):25-40. PubMed ID: 6787060 [TBL] [Abstract][Full Text] [Related]
45. Effects on 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione(FD-1) on the central nervous system: 1. Effects on monoamines in the brain. Toide K; Kitazato K; Unemi N Arch Int Pharmacodyn Ther; 1980 Oct; 247(2):243-56. PubMed ID: 6778400 [TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors. Arakawa M; Shimizu F; Sasagawa K; Inomata T; Shinkai K Gan; 1981 Apr; 72(2):220-5. PubMed ID: 6793441 [TBL] [Abstract][Full Text] [Related]
47. Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity. Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Chiba M Drug Metab Dispos; 2014 Sep; 42(9):1485-92. PubMed ID: 25002745 [TBL] [Abstract][Full Text] [Related]
48. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Fujii S; Kitano S; Ikenaka K; Shirasaka T Gan; 1979 Apr; 70(2):209-14. PubMed ID: 381088 [TBL] [Abstract][Full Text] [Related]
49. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934 [TBL] [Abstract][Full Text] [Related]
50. Human urinary metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftoraful). Benvenuto JA; Liehr JG; Winkler T; Farquhar D; Caprioli RM; Loo TL Cancer Res; 1979 Aug; 39(8):3199-201. PubMed ID: 378368 [TBL] [Abstract][Full Text] [Related]
51. Synthesis, structure, and conformation of anti-tumor agents in the solid and solution states: hydroxyl derivatives of Ftorafur. Stokes DM; Paul B; Alderfer JL; Wollman RM; Srikrishnan T Nucleosides Nucleotides Nucleic Acids; 2002; 21(11-12):863-82. PubMed ID: 12537027 [TBL] [Abstract][Full Text] [Related]
53. Enhanced accumulation of 5-fluorouracil in human tumors in athymic mice by co-administration of Ftorafur and uracil. Tang SG; Hornbeck CL; Byfield JE Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1687-9. PubMed ID: 6434499 [TBL] [Abstract][Full Text] [Related]
54. Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes. Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K Pharmacol Res Perspect; 2013 Oct; 1(1):e00009. PubMed ID: 25505563 [TBL] [Abstract][Full Text] [Related]
55. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578 [TBL] [Abstract][Full Text] [Related]
56. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397 [TBL] [Abstract][Full Text] [Related]
57. [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative]. Shirasaka T; Fukushima M; Shimamoto Y; Kimura Y; Ohshimo H; Imaoka T; Kimura A; Utsunomiya T; Fujii S Gan To Kagaku Ryoho; 1990 May; 17(5):1051-8. PubMed ID: 2334171 [TBL] [Abstract][Full Text] [Related]
58. [Biotransformation of ftorafur]. Kozhukhov AN Vopr Med Khim; 1981; 27(2):243-7. PubMed ID: 6792775 [TBL] [Abstract][Full Text] [Related]
59. Ftorafur: a self-limiting source of 5-fluorouracil? van Putten LM; Lelieveld P; Pantarotto C; Salmona M; Spreafico F Cancer Chemother Pharmacol; 1979; 3(1):61-6. PubMed ID: 119584 [No Abstract] [Full Text] [Related]
60. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil. Yamamiya I; Yoshisue K; Matsushima E; Nagayama S Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]